Aoxin Q&M's acquisition will raise its exposure to PCR testing demand: Deputy CEO
Add BT as a preferred source
AOXIN Q&M Dental Group is boosting its exposure in the Covid-19 testing space. The Catalist-listed company expects its acquisition of a stake in medical technology company Acumen Diagnostics to improve its top and bottom lines.
The deal is a "very good opportunity" for the company to expand its reach into the medtech business, which has been on a tear since the start of the Covid-19 pandemic, Aoxin Q&M's deputy chief executive Ryan San told The Business Times on Tuesday.
Shareholders can expect stronger financials as soon as the second half of 2021 ending December, and higher dividend payouts, he added.
TRENDING NOW
Firm loses wrongful dismissal case despite following termination clause
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
Soilbuild’s Lim Chap Huat sues Brookfield, claims it reneged on joint venture: WSJ
Citi, OCBC downgrade UOB post-Q2 results; RHB upgrades on valuation
